FOR IMMEDIATE RELEASE
April 6, 2023 – The Alpha-1 Global 5th International Research Conference and the 8th Patient Congress will be held from April 13-15 in Dublin, Ireland. Patient leaders, physicians and scientists from around the world will come together to discuss the latest developments in patient advocacy, clinical care and Alpha-1 Antitrypsin Deficiency (Alpha-1) research.
With a rich history of international collaboration, the Foundation is committed to Alphas worldwide and is proud to host representatives from over 25 countries over the course of 3 days. The commitment to the mission drives Alpha-1 Global each day to increase awareness, detection, and access to care for Alphas around the world.
Hosting the event in Dublin, Ireland brings together two international Foundations working in collaboration for Alphas around the globe. A special thank you to Alpha-1 Foundation Ireland and RCSI University of Medicine and Health Sciences (RCSI) for their partnership and important role in this biennial event. Conference attendees will visit RCSI on Friday night, April 14th for a reception and dinner and hear from esteemed Alpha-1 researchers during the conference including Professor Noel “Gerry” McElvaney, Professor and Chair of the Department of Medicine at RCSI University of Medicine and Health Sciences and Respiratory Physician at Beaumont Hospital. A special thank you to Professor McElvaney who has helped shape a robust research agenda with intriguing topics to be discussed by international medical and scientific experts and an equally interesting patient congress agenda. We are grateful for the commitment and leadership of Geraldine Kelly, Alpha-1 Foundation Ireland Chief Executive Officer, Dr. Tomás Carroll, Chief Scientist and Senior Lecturer in the Department of Medicine at RCSI and Professor Frank Doyle, associate professor of psychology at RCSI’s School of Population Health.
“We are delighted to welcome all attendees to this very exciting Alpha-1 Global Research Conference and Patient Congress. This is an exciting time in the field of Alpha-1 and this joint meeting gives an opportunity for researchers, clinicians and patients from all over the world to intermingle, exchange ideas and collaborate, all in the beautiful surroundings of Dublin, capital city of Ireland,” stated Professor Gerry McElvaney.
The program agenda for the meetings is available to view here.
The 2023 meeting will begin with the Alpha-1 Global 5th International Research Conference on Friday, April 14th. The goal of the Research Conference is to bring the global Alpha-1 research community together to forge partnerships that will bring us closer to a cure for Alpha-1 Antitrypsin Deficiency (Alpha-1). A multidisciplinary group of scientists and experts will present and discuss novel treatment paradigms in Alpha-1 to accelerate research towards a cure.
The event will continue with representatives from over 25 countries at the 8th Patient Congress on Saturday, April 15th. The Patient Congress will provide a platform for education, discussion and networking, to further the missions of Alpha-1 organizations around the world. The program will include research and therapeutic updates, journeys to get augmentation therapy approved and reimbursed, medical collaboration, patient engagement in research, advocacy advancement through public policy and clinical practice, mental and physical wellness, and the importance of awareness, testing and detection. We are committed to empowering patients to make informed decisions about their care and to take part in Alpha-1 research.
Michelle Hughes, Alpha-1 Patient and Alpha-1 Foundation Ireland Board Member exclaimed, “Bring it on! All of us Alphas here in Ireland are really looking forward to this historic weekend in Dublin as we welcome Alpha-1 doctors, researchers, and patients from across the Globe. It is an exceptional chance for us to enhance our knowledge of Alpha-1 and to share the wonderful camaraderie within the Alpha community here with our global friends. We know it will be a true Irish “meitheal” experience for all with plenty of smiles, fun and laughter along the way! Our sincere thanks and gratitude to all the team at the US Alpha-1 Foundation and Alpha-1 Foundation Ireland for hosting the event – we so appreciate all you have done and continue to do for us.”
This event provides the incredible opportunity for representatives from both the Alpha-1 patient and medical communities around the world to come together and connect. The goal is to provide Alphas with the most current and relevant information about Alpha-1 and we encourage you to gain a renewed vision and purpose for the task at hand.
About the Alpha-1 Foundation
Alpha-1 Antitrypsin Deficiency (Alpha-1) is a genetic (inherited) condition that is passed from parents to their children through their genes. Alpha-1 may result in serious lung disease in adults and/or liver disease at any age. The Alpha-1 Foundation, founded in 1995, is committed to finding a cure for Alpha-1 and to improving the lives of people affected by Alpha-1 worldwide. The Foundation has invested over $91 million to support Alpha-1 research and programs at 128 institutions in North America, Europe, South America, the Middle East, and Australia.
Contact: Jeanne Kushner
Director of Communications & Public Affairs
877-228-7321, ext. 204
